EndophthalmitisVision and hearingDrugPhase 2, Phase 3
What this study is
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
What's being tested
- Moxifloxacin
Intervention · DRUG
Intracameral injection
- Placebo
Intervention · DRUG
intracameral injection
Study details
- Official title
- Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
- Sponsor
- Jason Ahee, M.D.
- Conditions
- Endophthalmitis
- Enrolling
- 60,000 people
- Starts
- 2027-06-01
- Est. completion
- 2031-10
- Design
- Triple-blind, randomized, parallel groups, Phase 2, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 40 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Visually significant cataracts
You can't join if
- Allergy to fluoroquinolones, cobalamin (B12)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openZion Eye Institute
St. George, Utah, United States
- Jason Ahee, M.D. · Contact
Study team
Sponsor
Jason Ahee, M.D.
Study ID PIND 134134
Principal investigator
Jason Ahee, M.D.
Zion Therapeutics, LLC
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.